DRTS — Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: IL
- Exchange: NASDAQ
- Employees: 125
- Website: https://www.alphatau.com
Latest SEC filings for DRTS
- 6-K — 2026-08-10
- 6-K — 2026-05-18
- 6-K — 2026-05-18
- F-3 — 2026-04-28
- 6-K — 2026-03-09
- 20-F — 2026-03-09
- 6-K — 2026-01-29
- 6-K — 2026-01-06
- 6-K — 2026-01-05
- 6-K — 2025-12-18
Latest DRTS news
- — Alpha Tau to Participate in October Investor Conferences (globenewswire.com)
Educational tool only — not investment advice.